SCHEMBL29195783

SCHEMBL29195783

O=c1n(Cc2ccccc2)nc(Cc2c(F)cccc2Cl)n1CC1CCC(F)(F)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ LMNA P02545 2/20 0.40
▸ P2RX7 Q99572 2/20 0.38
▸ ADORA2A P29274 2/20 0.37
▸ ADORA2B P29275 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ PDE5A O76074 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ CX3CR1 P49238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29195769 0.91 P2RX7 (0.39) TP53MAPTLMNAP2RX7ADORA2A
SCHEMBL29195800 0.89 P2RX7 (0.40) LMNAP2RX7ADORA2AADORA2BKMT2A
SCHEMBL29195848 0.88 P2RX7 (0.41) LMNAP2RX7ADORA2AADORA2BKMT2A
SCHEMBL30309029 0.87 P2RX7 (0.38) LMNAP2RX7ADORA2AADORA2BKMT2A
SCHEMBL29195801 0.86 ADORA2A (0.38) TP53MAPTLMNAP2RX7ADORA2A
SCHEMBL29195810 0.85 P2RX7 (0.44) MAPTLMNAP2RX7ADORA2AADORA2B
SCHEMBL29195799 0.85 P2RX7 (0.39) LMNAP2RX7ADORA2AADORA2BKMT2A
SCHEMBL30309032 0.85 P2RX7 (0.40) LMNAP2RX7ADORA2AADORA2BALDH1A1
SCHEMBL29195788 0.83 LMNA (0.36) TP53LMNAP2RX7ADORA2AADORA2B
SCHEMBL29195759 0.81 P2RX7 (0.37) LMNAP2RX7ADORA2AADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368092-A1 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists BREYE THERAPEUTICS APS (DK) 2024-11-07 — — US disclosed
EP-4396181-A1 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS Breye Therapeutics ApS (DK) 2024-07-10 — — EP disclosed
CN-117881675-A 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists 布雷耶疗法有限公司 2024-04-12 — — CN disclosed
WO-2023031319-A1 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS AXXAM S.P.A. (IT) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368092-A1 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists P2RX3, P2RX7, P2RX2 TP53 3431/4885MAPT 3528/4885LMNA 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback